#1 Clinical Trials Search in Europe

Glatiramer Acetate

Glatiramer acetate, also known by the brand name Copaxone, is a medication that has been extensively studied in clinical trials for the treatment of multiple sclerosis (MS). This article explores various clinical trials investigating the safety, efficacy, and long-term effects of glatiramer acetate in different forms of MS, including relapsing-remitting MS, clinically isolated syndrome, and secondary progressive MS. We’ll examine how this drug works, its potential benefits, and its role in managing MS symptoms and disease progression.

Table of Contents

What is Glatiramer Acetate?

Glatiramer acetate is a medication used to treat multiple sclerosis (MS). It is also known by the brand names Copaxone, Cinnomer, and Osvimer[1][2][3]. This drug belongs to a class of medications called immunomodulators, which means it works by modifying the immune system’s response[4].

How Glatiramer Acetate Works

Glatiramer acetate works in several ways to help manage MS:

  • Immune system modulation: It modifies immune cells to produce high levels of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF). These factors help protect and support brain cells[1].
  • Blood-brain barrier crossing: The modified immune cells can cross the blood-brain barrier, which is a protective layer around the brain and spinal cord. Once inside, they release BDNF and other regulatory substances that can help protect nerve cells[1].
  • Anti-inflammatory effects: Glatiramer acetate may help reduce inflammation in the central nervous system, which is a key factor in MS progression[4].

Conditions Treated with Glatiramer Acetate

Glatiramer acetate is primarily used to treat multiple sclerosis, specifically:

  • Relapsing-Remitting Multiple Sclerosis (RRMS): This is the most common form of MS, characterized by periods of symptom flare-ups followed by periods of remission[5].
  • Clinically Isolated Syndrome (CIS): This refers to the first episode of neurological symptoms that might be the beginning of MS[6].
  • Secondary Progressive Multiple Sclerosis (SPMS): Some studies have explored the use of glatiramer acetate in this more advanced form of MS, where disability progressively accumulates[3].

How Glatiramer Acetate is Administered

Glatiramer acetate is typically administered in one of two ways:

  • Daily injection: A 20 mg dose is injected subcutaneously (under the skin) once daily[7].
  • Three times per week: A 40 mg dose is injected subcutaneously three times per week, with at least 48 hours between injections[2].

The injections are usually given in areas such as the back of the upper arms, front and outside of thighs, upper buttocks/rear hips, and stomach[1].

Effectiveness of Glatiramer Acetate

Clinical trials have shown that glatiramer acetate can be effective in managing MS in several ways:

  • Reducing relapse rates: It can help decrease the frequency of MS relapses or flare-ups[8].
  • Delaying disability progression: Some studies suggest it may slow down the worsening of disability in MS patients[8].
  • Reducing brain lesions: It may help reduce the number of new brain lesions seen on MRI scans[8].
  • Potentially slowing brain atrophy: Some research indicates it might help slow down the loss of brain volume that can occur in MS[8].

Potential Side Effects

Like all medications, glatiramer acetate can cause side effects. Common side effects may include:

  • Injection site reactions (redness, pain, swelling)[5]
  • Chest pain or flushing immediately after injection[5]
  • Shortness of breath[5]
  • Anxiety[5]

It’s important to discuss any side effects with your healthcare provider.

Ongoing Research

Researchers continue to study glatiramer acetate to better understand its effects and potential uses. Some areas of ongoing research include:

  • Use in other conditions: Some studies are exploring its potential use in conditions like Rett syndrome, a rare genetic neurological disorder[9].
  • Long-term effects: Researchers are studying the long-term safety and effectiveness of glatiramer acetate in MS patients[7].
  • Comparison with other treatments: Studies are comparing glatiramer acetate with other MS treatments to determine relative effectiveness[3].
Aspect Details
Drug Name Glatiramer Acetate (Copaxone)
Primary Use Treatment of Multiple Sclerosis (MS)
Forms of MS Studied Relapsing-Remitting MS, Clinically Isolated Syndrome, Secondary Progressive MS
Administration Subcutaneous injection (20 mg daily or 40 mg three times weekly)
Primary Outcomes Studied Relapse rates, disability progression, MRI lesions, brain atrophy
Safety Profile Generally well-tolerated; common side effects include injection site reactions
Long-term Studies Some trials have followed patients for up to 20 years or more
Additional Benefits Potential neuroprotective effects, improvement in quality of life

FAQ

  • What is glatiramer acetate and how does it work? Glatiramer acetate is a medication used to treat multiple sclerosis. It works by modifying the immune system's response, potentially reducing inflammation and protecting nerve fibers from damage. It's believed to stimulate certain immune cells that suppress the harmful immune response in MS.
  • What forms of multiple sclerosis has glatiramer acetate been studied for? Clinical trials have investigated glatiramer acetate for various forms of MS, including relapsing-remitting MS, clinically isolated syndrome (early signs of MS), and secondary progressive MS. It has shown potential benefits in delaying the progression of the disease and reducing relapse rates in these forms of MS.
  • How is glatiramer acetate administered? Glatiramer acetate is typically administered through subcutaneous (under the skin) injections. Different dosing regimens have been studied, including daily injections of 20 mg and three-times-weekly injections of 40 mg.
  • What are some common side effects of glatiramer acetate? Common side effects of glatiramer acetate may include injection site reactions (such as redness, pain, or swelling), flushing, chest pain, weakness, and infection. Most side effects are mild to moderate and tend to decrease over time. Serious side effects are rare but can occur.
  • How long have clinical trials been studying glatiramer acetate? Clinical trials have been studying glatiramer acetate for many years, with some long-term studies following patients for up to 20 years or more. These long-term studies help researchers understand the safety and effectiveness of the medication over extended periods of use.

Ongoing Clinical Trials on Glatiramer Acetate

  • Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Ireland +2

  • Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6

  • Study on the Safety and Effectiveness of Venetoclax with Fludarabine, Amsacrine, and Cytarabine for Patients with MDS, CMML, or Secondary AML Undergoing Stem Cell Transplantation

    Recruiting

    1 1 1 1
    Investigated drugs:
    Germany

  • Study on Stopping Dimethyl Fumarate and Drug Combination in Patients Aged 55+ with Inactive Relapsing-Remitting Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Pembrolizumab with Chemotherapy for Early-Stage Triple-Negative Breast Cancer in Patients with High TILs

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal

  • Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +4

  • Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study of Mosunetuzumab and Polatuzumab Vedotin Combination Treatment in Patients with B-Cell Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Spain

  • Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Ireland Italy Poland Portugal +2

Glossary

  • Multiple Sclerosis (MS): A chronic disease of the central nervous system where the immune system attacks the protective covering of nerves, leading to communication problems between the brain and the rest of the body.
  • Relapsing-Remitting Multiple Sclerosis (RRMS): The most common form of MS, characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • Clinically Isolated Syndrome (CIS): A first episode of neurologic symptoms caused by inflammation and demyelination in the central nervous system, which may or may not develop into MS.
  • Secondary Progressive Multiple Sclerosis (SPMS): A form of MS that develops following an initial relapsing-remitting course, characterized by a progressive worsening of neurologic function over time.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It ranges from 0 to 10, with higher scores indicating greater disability.
  • Glatiramer Acetate: A medication used to treat multiple sclerosis, believed to work by modifying the immune system's response to reduce inflammation and protect nerve fibers.
  • Annualized Relapse Rate (ARR): A measure used in MS studies to quantify the number of relapses a patient experiences per year.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique used to create detailed images of the brain and spinal cord, often used to diagnose and monitor MS.
  • T2 Lesions: Areas of damage in the brain or spinal cord caused by MS that can be seen on MRI scans. They appear as bright spots on T2-weighted MRI images.
  • Gadolinium-enhancing Lesions: Active MS lesions that can be seen on MRI scans after the injection of a contrast agent called gadolinium. These lesions indicate areas of active inflammation.

References

  1. https://clinicaltrials.gov/study/NCT02023424
  2. https://clinicaltrials.gov/study/NCT04928313
  3. https://clinicaltrials.gov/study/NCT03315923
  4. https://clinicaltrials.gov/study/NCT00819195
  5. https://clinicaltrials.gov/study/NCT00947752
  6. https://clinicaltrials.gov/study/NCT00910598
  7. https://clinicaltrials.gov/study/NCT00203021
  8. https://clinicaltrials.gov/study/NCT00666224
  9. https://clinicaltrials.gov/study/NCT02153723